Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed

Here's your news in brief: Janssen Biotech Inc.'s Tremfya (guselkumab) became the fourth novel interleukin-targeting antibody approved by FDA in 2017 with its July 13 clearance for plaque psoriasis.

The Janssen IL-23 blocker is the twenty-fourth novel agent approved by the Center for Drug Evaluation and Research (CDER) in 2017 as part of